MHRAsafety guidance83% confidence
Guidance: Best practice guidance on patient information leaflets
Source: MHRA
Why This Matters
Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to UCB Biopharma.
Regulatory Analysis
This guidance sets out the legal framework for patient information leaflets as described in EU and national legislation and best practice in the area of information design.
Supporting Context
- Therapeutic area
- Neurology · SLC6A1-NDD
- Sub-indication
- General
Related signal: UCB Biopharma initiates SLC6A1-NDD natural history study to inform future clinical trials